Blog Menu

Meet the Attorney: Trent Miracle

Attorney Trent Miracle decided to become a lawyer because he wanted to help people who have the odds stacked against them.

pharmaceutical attorneys“You are not alone, but you alone can make the decision to stand up for yourself,” Trent said. “Once you do that, we are here to help you with the rest.”

With more than 20 years of experience helping individuals who have been harmed by dangerous drugs and defective medical devices, Trent is a leader in the Pharmaceutical Litigation Group of Simmons Hanly Conroy. Through the years, Trent has worked with thousands of people in cases against large pharmaceutical companies.

With a national reputation in the area of pharmaceutical litigation, Trent and his fellow attorneys have secured nearly $360 million in settlements on behalf of their clients harmed by major pharmaceutical drugs like Bextra, Yaz, Vioxx, Ortho Evra, and Ephedra.

But Trent’s successes extend beyond the growth of the firm. With a career highly focused on fighting for clients, Trent consistently gives personal attention to the men and women he helps.

“A day doesn’t go by that someone on my team or myself responds to e-mails from clients, calls a client back or responds to an after-hours call from a client,” he said.… Read the rest


The Must-Know Facts about Blood-Thinning Medications

Blood thinning medications are used to prevent blood clots. Blood clots are health risks that increase chances of stroke, heart attack, and various other health issues. Warfarin is one of the original blood thinners and has been on the market since the 1950s. Warfarin proved to have some issues over the years, though. Namely, its dangerous interactions with other medicines and food as well as the need for regular blood testing.

More recent blood thinners such as Xarelto and Pradaxa have gained some popularity. Designed as alternatives to Warfarin, Xarelto and Pradaxa have negative aspects as well. If you or a loved one has been prescribed a blood-thinning medication, keep reading to learn more about these two popular medications.

Xarelto vs Pradaxa


Xarelto is an alternative anticoagulant with many uses. There are also many serious and potentially fatal Xarelto side effects, which has increased the need for Xarelto lawsuits. The drug is approved for use to reduce stroke and blood clot risk in people with atrial fibrillation. It is also used to treat deep vein thrombosis and pulmonary embolism. For hip and knee surgery patients, Xarelto helps to reduce the risk of blood clots in legs and lungs.

It was developed as an alternative to Warfarin because it does not require regular blood monitoring, which can be time consuming.… Read the rest


Pharmaceutical News Wrap Up: December 2014

The pharmaceutical attorneys at Simmons Hanly Conroy understand the importance of staying up to date on the latest headlines. Below is a list of some of the most recent pharmaceutical news concerning U.S. Food and Drug Administration (FDA) recalls, approvals and warning label changes, medical studies and other pharmaceutical news taking place throughout the world.

Read the rest

FDA Advisers Shown to Have Questionable Financial Ties

In July 2014, an adviser on a U.S. Food and Drug Administration (FDA) gynecology panel stepped down after he was questioned about conflicts of interest. It was later discovered that this panel member had received payments from the maker of the device he was evaluating. The FDA had not made this clear to the public. Such incidents influenced The Wall Street Journal to look into the relationship between the FDA, its expert advisers, and their ties to devices being evaluated.

The Wall Street Journal analysis of corporate, state, and federal data showed that some FDA panel experts have ties that could undermine objective panel rulings. Only 1% of these connections were publically acknowledged by the FDA.

Of the 122 members on panels evaluating gynecology, cardiology, and orthopedics devices, one-third had received compensation from a medical-device company. In this analysis, compensation includes anything from sponsored travel to money and research grants. Additionally, nearly 10 percent of the panel members had received compensation from the company whose device they were evaluating. These findings show a conflict of interest from the FDA advisers and the devices they evaluate.

Committees that sit on FDA panels are usually influential in the FDA’s decisions. The agency often follows the advice of their committee members when approving devices and placing regulations.… Read the rest


The History of Risperdal FDA Warnings

Risperdal was approved by the U.S. Food and Drug Administration (FDA) in 1994. It is recognized as a medication used to treat psychological issues. The antipsychotic drug is approved for use in patients with schizophrenia, schizoaffective disorder, bipolar disorder, and autism with irritability. Despite the drug’s effectiveness for these disorders, Risperdal side effects can be life changing or life threatening for people of different age groups.

In response, the FDA issued a black-box warning for Risperdal in 2005. The administration issued this alert so elderly users were aware of the fatal Risperdal side effects. Based on research at that time, there was a significantly higher risk of death in elderly individuals taking Risperdal. The black-box warning, the strictest warning given by the FDA, on the Risperdal bottle states that Risperdal use is not approved in elderly patients and can cause death in elderly patients.

Before this FDA black box warning, Risperdal was used freely in elderly patients with dementia induced psychosis. Even though Risperdal was never approved for use in elder patients with dementia, it was promoted for this by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. In 2013 Janssen Pharmaceuticals pleaded guilty to misbranding the drug and promoting it for use in elderly patients.… Read the rest

157 queries. 1.323 seconds